The evidence for the HPV vaccine's cancer-preventing effectiveness is not ambiguous. It is not preliminary. And it does not come from clinical trials that might be dismissed as controlled or manufacturer-influenced.
It comes from the real-world population data of entire countries.
Sweden reported an 88 percent reduction in invasive cervical cancer among women vaccinated before age 17. England reported an 87 percent reduction among women vaccinated between ages 12 and 13. Denmark reported an 86 percent reduction in the vaccinated cohort. These are not studies of immune responses or precancerous lesions — they are direct measurements of actual invasive cancer in actual people, conducted by national health registries over years of follow-up.
The CIDRAP Vaccine Integrity Project describes these results as among the most compelling real-world proof-of-concept for a cancer-prevention vaccine ever documented. For any other public health intervention, data of this quality would be treated as definitive.
Why This Matters
Against this evidence, a specific and documented concern has emerged in the United States: the reconstituted Advisory Committee on Immunization Practices (ACIP) — the federal body whose recommendations determine HPV vaccine insurance coverage for millions of Americans — has added four organizations with documented histories of vaccine skepticism as non-voting liaison members, and has signaled that its newly reoriented charter will involve re-examining existing HPV vaccine recommendations alongside "alternatives" to vaccines for disease prevention.
As Stanford infectious disease expert Dr. Jake Scott observed in a CIDRAP op-ed on the ACIP charter changes: "The old assignment was to figure out how to use vaccines well. The new one, in plain terms, is to build the case against them."
What We Know So Far
The international HPV vaccine effectiveness data has accumulated over more than 15 years of population-level follow-up since the vaccine was introduced in multiple countries simultaneously. These are not small studies.
Sweden: A study of approximately 1.7 million girls and women followed from age 10 onward found that women vaccinated before age 17 had an 88 percent lower rate of invasive cervical cancer compared to unvaccinated women. The reduction was largest and earliest among women vaccinated before age 17 and declined progressively with age at vaccination — a pattern that directly maps onto the known biology of HPV clearance and the vaccine's greater effectiveness when given before exposure.
England: England implemented the HPV vaccine for girls aged 12 to 13 in 2008, creating a generation of vaccinated women now reaching the typical age of cervical cancer incidence. Data published in The Lancet in 2021, drawn from England's national cervical screening and cancer registry, showed an 87 percent reduction in invasive cervical cancer among women vaccinated at the target age, with almost complete elimination of cancers caused by HPV 16 and 18 — the two types responsible for the majority of cervical cancers. More recently, a 2026 Lancet analysis of cervical cancer mortality in England found zero deaths in the most-vaccinated birth cohort versus 23.1 expected — a 100% mortality reduction in that group.
Denmark: Danish population data, consistent with the Sweden and England findings, produced an 86 percent reduction in the vaccinated cohort. The consistency of the 86 to 88 percent range across all three independent national datasets is itself a form of evidence — independent health systems applying independent methodologies reaching the same conclusion.
Beyond cervical cancer, Gardasil 9 is FDA-approved to prevent six additional cancer types, including anal, oropharyngeal, vaginal, vulvar, and penile cancers.
The ACIP Concern Explained
As detailed in CIDRAP's coverage of the ACIP charter changes, HHS Secretary Robert F. Kennedy Jr. fired all 17 prior ACIP members and replaced them with a smaller panel that a federal court found to be "distinctly unqualified" — with only six of 15 members having any meaningful experience in vaccines. Two subsequent charter rewrites have broadened membership qualifications specifically to include people who would not have qualified under the previous evidence-based criteria.
The newly expanded list of non-voting liaison organizations, as reported by CNN, now includes the Independent Medical Alliance, Physicians for Informed Consent, the Medical Academy of Pediatrics and Special Needs, and the Association of American Physicians and Surgeons — groups that maintain that vaccine risks are underreported or hidden from the public and that vaccine benefits may not outweigh their harms. These groups now have a formalized role in providing input to ACIP's deliberations.
The charter language also specifically directs ACIP to consider "alternatives" to vaccines for disease prevention — a framing conspicuously misaligned with a committee whose documented effectiveness lies in setting vaccine recommendations, not alternative medicine frameworks.
For HPV vaccines specifically, the practical stakes are high: if ACIP were to narrow, significantly qualify, or eliminate its recommendation for routine HPV vaccination, the insurance coverage mandate that guarantees cost-free HPV vaccination for adolescents would be at risk. The result would be reduced vaccine uptake in exactly the population — adolescents before first sexual exposure — where the vaccine's effectiveness is greatest.
What Doctors and Experts Say
Dr. Jake Scott, an infectious disease specialist at Stanford University, framed the concern precisely in a CIDRAP op-ed on the ACIP situation: "If ACIP appointees are told to consider only the risks of vaccines, rather than also considering their benefits, 'you have built a body designed to recommend fewer of them.' Fewer recommendations mean narrower coverage, and the families with the least cushion feel it first." On the specific HPV evidence, Scott has written that the real-world population data from Sweden, England, and Denmark show what clinical trials predicted — this vaccine prevents cancer at a population level.
Paul Offit, MD, of Children's Hospital of Philadelphia, has warned more broadly about the direction of ACIP: "What [Kennedy] is doing is incredibly dangerous. I just feel like we're slowly approaching this cliff and about to fall off in slow motion."
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Study type: National population-level cancer registry data (Sweden ~1.7M participants; England national registry with 13.7M women-years of follow-up; Denmark national cohort)
- Vaccine studied: Bivalent and/or quadrivalent HPV vaccines (precursors to current Gardasil 9)
- What it found: 86–88% reductions in invasive cervical cancer in vaccinated cohorts across three independent national health systems
- What this does not address: All potential vaccine-adverse event concerns, which are real and should be monitored — though no serious safety signal has emerged from decades of surveillance across hundreds of millions of doses
- Current status: No evidence has emerged that would justify narrowing or eliminating the standard-of-care recommendation for routine HPV vaccination in adolescents aged 9 to 26
Who Is Most Affected?
- Adolescents aged 9 to 26, for whom the HPV vaccine is currently recommended and covered free by the Vaccines for Children program
- Families who have not yet vaccinated adolescent children may face reduced access or coverage if ACIP recommendations change
- Unvaccinated adults up to age 45 who have had a shared decision-making conversation with their physician
- People living with HIV, who face a dramatically elevated risk of HPV-related cancers and for whom the vaccine offers a particularly significant benefit
What You Can Do Now
If your child has not yet received the HPV vaccine, schedule it now rather than waiting for the outcome of the ACIP review process, which remains legally contested and uncertain.
HPV vaccination before first sexual exposure provides the strongest protection. Two doses are recommended for children under 15; three doses for adolescents 15 and older and all adults.
If you or a child in your care is between 27 and 45, discuss the vaccine with your physician — it is FDA-approved for this age range after a shared decision-making conversation.
Adults with HIV who have not been vaccinated should specifically ask their HIV care provider about Gardasil 9.
What Happens Next
The ACIP legal situation — including the underlying American Academy of Pediatrics v. Kennedy lawsuit and the ongoing quorum crisis — continues to evolve. CIDRAP's State of US Vaccine Policy series provides the most detailed ongoing tracking of the legal and policy developments. MedicalDaily will report on any ACIP vote, recommendation change, or court decision that affects HPV vaccine policy.
The Bottom Line
The HPV vaccine has produced 86 to 88 percent reductions in invasive cervical cancer across three independent national health systems, representing the most compelling real-world cancer prevention evidence in modern medicine. The federal committee responsible for maintaining the recommendation that makes this vaccine available to adolescents at no cost has been reconstituted under conditions that experts describe as designed to reach a different outcome. Parents who have not yet vaccinated their adolescent children should do so now.
